NOVA.STU Novo Nordisk A/S

- EUR
Market cap
-
P/E
10.2x
P/B
5.33x
ROE
62.9%
Dividend yield
2.19%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NOVA.STU undervalued?

Graham number

The Graham number of Novo Nordisk A/S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novo Nordisk A/S fundamental analysis

No fundamental analysis for Novo Nordisk A/S yet.

Novo Nordisk A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.